146 related articles for article (PubMed ID: 21804501)
1. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
Kabir MA; Ishaque SM; Ali MS; Mahmuduzzaman M; Hasan M
Mymensingh Med J; 2011 Jul; 20(3):397-401. PubMed ID: 21804501
[TBL] [Abstract][Full Text] [Related]
2. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
Majeed M; Nagabhushanam K; Natarajan S; Sivakumar A; Ali F; Pande A; Majeed S; Karri SK
Nutr J; 2016 Feb; 15():21. PubMed ID: 26922379
[TBL] [Abstract][Full Text] [Related]
3. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
Bustos Fernández LM; Man F; Lasa JS
Dig Dis; 2023; 41(5):798-809. PubMed ID: 36630947
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
McFarland LV
World J Gastroenterol; 2010 May; 16(18):2202-22. PubMed ID: 20458757
[TBL] [Abstract][Full Text] [Related]
5. Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome.
Xie Y; Zhou G; Xu Y; He B; Wang Y; Ma R; Chang Y; He D; Xu C; Xiao Z
Pain Res Manag; 2019; 2019():7890461. PubMed ID: 31531150
[TBL] [Abstract][Full Text] [Related]
6. Irritable Bowel Syndrome: Effects of a Probiotic Combination in Reducing Stress Response and Symptoms Associated With Irritable Bowel Syndrome.
Ross SM
Holist Nurs Pract; 2024 Mar-Apr 01; 38(2):120-122. PubMed ID: 38363971
[No Abstract] [Full Text] [Related]
7. [Thirty two cases of diarrhea-predominant irritable bowel syndrome treated by ginger-partitioned moxibustion and acupoint application in dog days].
Gao F
Zhongguo Zhen Jiu; 2014 Mar; 34(3):218. PubMed ID: 24843956
[No Abstract] [Full Text] [Related]
8. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.
Mansour-Ghanaei F; Dehbashi N; Yazdanparast K; Shafaghi A
World J Gastroenterol; 2003 Aug; 9(8):1832-3. PubMed ID: 12918131
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Saccharomyces boulardii CNCM I-745 in Adult Indian Patients with Diarrhoea: A Real-world, Multicentre, Retrospective, Comparative Study.
Pal BB; Bandagi RV; Pebbili KK; Rathod R; Kotak B; Dhanaki G; Shah S
Drugs Real World Outcomes; 2024 Jun; 11(2):309-316. PubMed ID: 38581564
[TBL] [Abstract][Full Text] [Related]
10. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
Abbas Z; Yakoob J; Jafri W; Ahmad Z; Azam Z; Usman MW; Shamim S; Islam M
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
[TBL] [Abstract][Full Text] [Related]
11. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
12. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
[TBL] [Abstract][Full Text] [Related]
13. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Yoon JS; Sohn W; Lee OY; Lee SP; Lee KN; Jun DW; Lee HL; Yoon BC; Choi HS; Chung WS; Seo JG
J Gastroenterol Hepatol; 2014 Jan; 29(1):52-9. PubMed ID: 23829297
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
Pineton de Chambrun G; Neut C; Chau A; Cazaubiel M; Pelerin F; Justen P; Desreumaux P
Dig Liver Dis; 2015 Feb; 47(2):119-24. PubMed ID: 25488056
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
Sisson G; Ayis S; Sherwood RA; Bjarnason I
Aliment Pharmacol Ther; 2014 Jul; 40(1):51-62. PubMed ID: 24815298
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.
Begtrup LM; de Muckadell OB; Kjeldsen J; Christensen RD; Jarbøl DE
Scand J Gastroenterol; 2013 Oct; 48(10):1127-35. PubMed ID: 23957590
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.
Ducrotté P; Sawant P; Jayanthi V
World J Gastroenterol; 2012 Aug; 18(30):4012-8. PubMed ID: 22912552
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome.
Stevenson C; Blaauw R; Fredericks E; Visser J; Roux S
Nutrition; 2014 Oct; 30(10):1151-7. PubMed ID: 25194614
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating.
Jafari E; Vahedi H; Merat S; Momtahen S; Riahi A
Arch Iran Med; 2014 Jul; 17(7):466-70. PubMed ID: 24979556
[TBL] [Abstract][Full Text] [Related]
20. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
Lorenzo-Zúñiga V; Llop E; Suárez C; Alvarez B; Abreu L; Espadaler J; Serra J
World J Gastroenterol; 2014 Jul; 20(26):8709-16. PubMed ID: 25024629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
